This HTML5 document contains 144 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n12http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/wikipedia/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n21http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/pharmgkb/
n6http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/kegg-compound/
foafhttp://xmlns.com/foaf/0.1/
n25http://linked.opendata.cz/resource/mesh/concept/
n34http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/pdb/
n4http://linked.opendata.cz/resource/drugbank/company/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/pubchem-compound/
n15http://linked.opendata.cz/resource/drugbank/mixture/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/pubchem-substance/
n18http://bio2rdf.org/drugbank:
n7http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/kegg-drug/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/drugbank/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/iuphar/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/guide-to-pharmacology/
admshttp://www.w3.org/ns/adms#
n33http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/national-drug-code-directory/
n19http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n24http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/chemspider/
n16http://www.drugs.com/cdi/
n28http://www.rxlist.com/cgi/generic2/
n10http://linked.opendata.cz/resource/drugbank/property/
n14http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
n9http://linked.opendata.cz/resource/drugbank/drug/DB00356/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n27http://linked.opendata.cz/resource/atc/
n26http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00356
rdf:type
n3:Drug
n3:description
A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202)
n3:dosage
n23:271B5ED5-363D-11E5-9242-09173F13E4C5 n23:271B5ED6-363D-11E5-9242-09173F13E4C5 n23:271B5ED3-363D-11E5-9242-09173F13E4C5 n23:271B5ED4-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Dong DL, Luan Y, Feng TM, Fan CL, Yue P, Sun ZJ, Gu RM, Yang BF: Chlorzoxazone inhibits contraction of rat thoracic aorta. Eur J Pharmacol. 2006 Sep 18;545(2-3):161-6. Epub 2006 Jun 29. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16859676 # Park JY, Kim KA, Park PW, Ha JM: Effect of high-dose aspirin on CYP2E1 activity in healthy subjects measured using chlorzoxazone as a probe. J Clin Pharmacol. 2006 Jan;46(1):109-14. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16397290 # Wan J, Ernstgard L, Song BJ, Shoaf SE: Chlorzoxazone metabolism is increased in fasted Sprague-Dawley rats. J Pharm Pharmacol. 2006 Jan;58(1):51-61. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16393464
n3:group
approved
n3:indication
For the relief of discomfort associated with acute painful musculoskeletal conditions.
n3:manufacturer
n4:271B5ECF-363D-11E5-9242-09173F13E4C5 n4:271B5ECD-363D-11E5-9242-09173F13E4C5 n4:271B5ECE-363D-11E5-9242-09173F13E4C5 n4:271B5EC7-363D-11E5-9242-09173F13E4C5 n4:271B5EC8-363D-11E5-9242-09173F13E4C5 n4:271B5EC5-363D-11E5-9242-09173F13E4C5 n4:271B5EC6-363D-11E5-9242-09173F13E4C5 n4:271B5ECB-363D-11E5-9242-09173F13E4C5 n4:271B5ECC-363D-11E5-9242-09173F13E4C5 n4:271B5EC9-363D-11E5-9242-09173F13E4C5 n4:271B5ECA-363D-11E5-9242-09173F13E4C5 n4:271B5EC4-363D-11E5-9242-09173F13E4C5
owl:sameAs
n18:DB00356 n19:DB00356
dcterms:title
Chlorzoxazone
adms:identifier
n6:C07931 n7:D00771 n9:3655 n12:Chlorzoxazone n20:46507755 n21:PA448971 n22:2733 n29:2322 n30:2322 n31:2632 n32:DB00356 n33:0045-0325-60 n34:CLW
n3:mechanismOfAction
Chlorzoxazone inhibits degranulation of mast cells, subsequently preventing the release of histamine and slow-reacting substance of anaphylaxis (SRS-A), mediators of type I allergic reactions. Chlorzoxazone also may reduce the release of inflammatory leukotrienes. Chlorzoxazone may act by inhibiting calcium and potassium influx which would lead to neuronal inhibition and muscle relaxation. Data available from animal experiments as well as human study indicate that chlorzoxazone acts primarily at the level of the spinal cord and subcortical areas of the brain where it inhibits multisynaptic reflex arcs involved in producing and maintaining skeletal muscle spasm
n3:packager
n4:271B5EC0-363D-11E5-9242-09173F13E4C5 n4:271B5EBD-363D-11E5-9242-09173F13E4C5 n4:271B5EBE-363D-11E5-9242-09173F13E4C5 n4:271B5EB3-363D-11E5-9242-09173F13E4C5 n4:271B5EB4-363D-11E5-9242-09173F13E4C5 n4:271B5EB1-363D-11E5-9242-09173F13E4C5 n4:271B5EB2-363D-11E5-9242-09173F13E4C5 n4:271B5EAF-363D-11E5-9242-09173F13E4C5 n4:271B5EB0-363D-11E5-9242-09173F13E4C5 n4:271B5EAD-363D-11E5-9242-09173F13E4C5 n4:271B5EAE-363D-11E5-9242-09173F13E4C5 n4:271B5EBB-363D-11E5-9242-09173F13E4C5 n4:271B5EBC-363D-11E5-9242-09173F13E4C5 n4:271B5EB9-363D-11E5-9242-09173F13E4C5 n4:271B5EBA-363D-11E5-9242-09173F13E4C5 n4:271B5EB7-363D-11E5-9242-09173F13E4C5 n4:271B5EB8-363D-11E5-9242-09173F13E4C5 n4:271B5EB5-363D-11E5-9242-09173F13E4C5 n4:271B5EB6-363D-11E5-9242-09173F13E4C5 n4:271B5EA3-363D-11E5-9242-09173F13E4C5 n4:271B5EA4-363D-11E5-9242-09173F13E4C5 n4:271B5EA1-363D-11E5-9242-09173F13E4C5 n4:271B5EA2-363D-11E5-9242-09173F13E4C5 n4:271B5EA0-363D-11E5-9242-09173F13E4C5 n4:271B5EAB-363D-11E5-9242-09173F13E4C5 n4:271B5EAC-363D-11E5-9242-09173F13E4C5 n4:271B5EA9-363D-11E5-9242-09173F13E4C5 n4:271B5EAA-363D-11E5-9242-09173F13E4C5 n4:271B5EA7-363D-11E5-9242-09173F13E4C5 n4:271B5EA8-363D-11E5-9242-09173F13E4C5 n4:271B5EA5-363D-11E5-9242-09173F13E4C5 n4:271B5EA6-363D-11E5-9242-09173F13E4C5 n4:271B5EC3-363D-11E5-9242-09173F13E4C5 n4:271B5EC1-363D-11E5-9242-09173F13E4C5 n4:271B5EC2-363D-11E5-9242-09173F13E4C5 n4:271B5EBF-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Chlorzoxazone is rapidly metabolized and is excreted in the urine, primarily in a conjugated form as the glucuronide.
n3:synonym
5-chloro-2-Benzoxazolinone Chlorzoxazone 2-hydroxy-5-chlorobenzoxazole 5-chloro-2-Hydroxybenzoxazole Chlorzoxane Clorzoxazona 5-chloro-2-Benzoxazolone Chlorzoxazonum Chlorzoxazona 5-chlorobenzoxazolin-2-one Clorzoxazone 5-chloro-3H-benzooxazol-2-one Chlorzoxazon 5-chloro-2(3H)-benzoxazolone 5-Chlorobenzoxazolidone 5-chloro-2-Benzoxazolol
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 440 mg/kg; Oral, rat: LD<sub>50</sub> = 763 mg/kg; Symptoms of overdose include diarrhea, dizziness, drowsiness, headache, light-headedness, nausea, and vomiting.
n3:foodInteraction
Take without regard to meals. Avoid alcohol.
n3:mixture
n15:271B5E9B-363D-11E5-9242-09173F13E4C5 n15:271B5E9C-363D-11E5-9242-09173F13E4C5 n15:271B5E99-363D-11E5-9242-09173F13E4C5 n15:271B5E9A-363D-11E5-9242-09173F13E4C5 n15:271B5E9F-363D-11E5-9242-09173F13E4C5 n15:271B5E9D-363D-11E5-9242-09173F13E4C5 n15:271B5E9E-363D-11E5-9242-09173F13E4C5 n15:271B5E98-363D-11E5-9242-09173F13E4C5
n3:proteinBinding
13-18%
n3:synthesisReference
Marsh, D.F.; US. Patent 2,895,877; July 21, 1959; assigned to McNeil Laboratories, Inc.
n24:hasConcept
n25:M0004217
foaf:page
n14:par1317.shtml n16:chlorzoxazone.html n28:chlorzox.htm
n3:IUPAC-Name
n10:271B5EDB-363D-11E5-9242-09173F13E4C5
n3:InChI
n10:271B5EE1-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n10:271B5EE0-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n10:271B5EDD-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n10:271B5EDE-363D-11E5-9242-09173F13E4C5
n3:SMILES
n10:271B5EDF-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n10:271B5EF1-363D-11E5-9242-09173F13E4C5 n10:271B5ED9-363D-11E5-9242-09173F13E4C5
n3:logP
n10:271B5EF3-363D-11E5-9242-09173F13E4C5 n10:271B5EDA-363D-11E5-9242-09173F13E4C5 n10:271B5ED7-363D-11E5-9242-09173F13E4C5
n3:logS
n10:271B5ED8-363D-11E5-9242-09173F13E4C5
n26:hasATCCode
n27:M03BB03
n3:H-Bond-Acceptor-Count
n10:271B5EE7-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n10:271B5EE8-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n10:271B5EE2-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n10:271B5EE3-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n10:271B5EE5-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n10:271B5EE4-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n10:271B5EE6-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
95-25-0
n3:category
n3:containedIn
n8:271B5ED1-363D-11E5-9242-09173F13E4C5 n8:271B5ED2-363D-11E5-9242-09173F13E4C5 n8:271B5ED0-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n10:271B5EED-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n10:271B5EEF-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n10:271B5EF0-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n10:271B5EF2-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n10:271B5EEC-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n10:271B5EEB-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n10:271B5EEE-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n10:271B5EDC-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n10:271B5EE9-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n10:271B5EEA-363D-11E5-9242-09173F13E4C5